Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE2 | O96020 | 9/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 9/20 | 0.44 |
| ▸ | CDK2 | P24941 | 9/20 | 0.44 |
| ▸ | CCNB2 | O95067 | 6/20 | 0.44 |
| ▸ | CDK1 | P06493 | 6/20 | 0.44 |
| ▸ | CDK4 | P11802 | 6/20 | 0.44 |
| ▸ | CCNB1 | P14635 | 6/20 | 0.44 |
| ▸ | CCND1 | P24385 | 6/20 | 0.44 |
| ▸ | CCND2 | P30279 | 6/20 | 0.44 |
| ▸ | CCND3 | P30281 | 6/20 | 0.44 |
| ▸ | CCNB3 | Q8WWL7 | 6/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30025652 | 0.78 | CYP3A4 (0.41) | CCNE2CCNE1CDK2CCNB2CDK1 | |
| SCHEMBL30058516 | 0.78 | CYP3A4 (0.41) | CDK1CYP3A4CYP1A2CYP2D6ALDH1A1 | |
| SCHEMBL23535243 | 0.78 | CYP3A4 (0.41) | CCNE2CCNE1CDK2CCNB2CDK1 | |
| SCHEMBL23534517 | 0.78 | CYP3A4 (0.41) | CCNE2CCNE1CDK2CCNB2CDK1 | |
| SCHEMBL23534056 | 0.78 | CYP3A4 (0.41) | CDK1CYP3A4CYP1A2CYP2D6ALDH1A1 | |
| SCHEMBL18283425 | 0.75 | LMNA (0.41) | CYP3A4ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL30024829 | 0.75 | LMNA (0.41) | CYP3A4ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL23534051 | 0.67 | PLA2G2D (0.44) | — | |
| SCHEMBL1178069 | 0.67 | KMT2A (0.58) | CYP3A4CYP1A2ALDH1A1MEN1POLB | |
| SCHEMBL23534419 | 0.67 | SSTR2 (0.38) | CCNE2CCNE1CDK2CYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4076459-B1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12595248-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-04-07 | — | — | US | disclosed |
| US-20230108114-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-04-06 | — | — | US | disclosed |
| EP-4076459-A1 | PRMT5 INHIBITORS | Merck Sharp & Dohme LLC (US) | 2022-10-26 | — | — | EP | disclosed |
| WO-2021126728-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021126729-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021126728-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595248-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT6 | CCNE2 2287/4885CCNE1 823/4885CDK2 510/4885 |
| US-20230108114-A1 | PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | CCNE2 1999/4885CCNE1 843/4885CDK2 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.